Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This experimental antimicrobial gel formulation, developed by researchers at the University of Santiago de Compostela, combines 0.20% chlorhexidine (CHX) with cymenol (o-cymen-5-ol). Chlorhexidine is a well-established cationic bisbiguanide antiseptic that disrupts bacterial cell membranes, while cymenol is a small molecule antimicrobial agent that provides complementary activity against oral biofilms. The formulation is specifically designed to target dental plaque and salivary flora. In a randomized crossover clinical trial involving healthy volunteers, a single application of the gel demonstrated potent immediate antimicrobial effects and substantivity (persistence of action) for up to seven hours, performing similarly to standard 0.20% chlorhexidine-only gels. It is currently being investigated for its efficacy in maintaining oral hygiene and preventing biofilm-related dental conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine + cymenol gel.